Notícias

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for obesity. The data show proof of concept with favorable tolerability and low reported adverse events in the trial setting. Pfizer has started Phase 3 trials and outlined a broader clinical program for berobenatide as part of its late-stage obesity pipeline. For investors tracking NYSE:PFE, this update offers a clearer view of how Pfizer is positioning itself in the...

With an annual dividend yield of 6.57%, Pfizer Inc. (NYSE:PFE) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s […]

Passive income arrives while you sleep, commute, or vacation. That appeal drives dividend investing: a paycheck every quarter regardless of market conditions or work hours. Layoff announcements have rattled white-collar industries through the first half of 2026, and essentials costs climb faster than most household raises. Building a cash-flowing portfolio is one of the few ... 3 Stocks With a Yield Over 6% For Passive Income Investors

Pfizer Inc. (NYSE:PFE) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA approved an expanded indication for Hympavzi to include patients with hemophilia A or B 12 years and older with inhibitors and pediatric patients with or without inhibitors. Hympavzi is […]

While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.

Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.

Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy

Pfizer (NYSE:PFE) reported Phase 3 data for BRAFTOVI in BRAF V600E-mutated metastatic colorectal cancer and TALZENNA in HRR-mutated metastatic prostate cancer. The company presented the long term results at ASCO and published them in leading medical journals. The data show meaningful survival benefits in high-need cancer populations and reinforce Pfizer’s oncology positioning. For investors following NYSE:PFE, these oncology readouts add another piece to the story that has recently centered...

Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.

Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.

Pfizer (NYSE:PFE) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that ... This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees

At $25.60, Pfizer (NYSE:PFE) sits in Hold territory on Wall Street’s consensus. The headline 6.7% dividend yield is reason to pause rather than pounce. A payout that fat usually reflects a market pricing in trouble, and the under-the-radar concern is whether stretched operating cash flow can fund both the dividend and the debt stack from ... A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25

Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.

RBC Upgrade Signals Stabilizing Outlook After 2026 Selloff

Investing.com -- Pfizer shares may have found a more balanced risk-reward profile after a sharp decline this year, prompting RBC Capital Markets to upgrade the drugmaker to Sector Perform from Underperform while maintaining its $25 price target. The brokerage said the stock's roughly 11% pullback from its 2026 highs has brought valuation in line with its expectations, reducing the downside risks it had previously highlighted.

Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and th

Pfizer's (PFE) risk-reward profile has become more balanced following recent share weakness, with th

MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.

Pre-Market Stock Futures: Futures are trading lower after the stock market tried to take a cue from Monday’s action, and things didn’t work out quite as well on Tuesday. Once again, the market gapped open higher as the “Buy the dip” legions came in to ride what they thought would be another wave higher, only ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: BILL Holdings, Cava Group, Entergy, GlobalFoundries, Hess Midstream, Nike, Pfizer, SharkNinja, STMicroelectronics, and More

By Chris Prentice and Maggie Fick NEW YORK/LONDON, June 10 (Reuters) - Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to

Pfizer (NYSE:PFE) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight quarterly EPS beats before stumbling in Q1. Yet the stock is up only 6.37% YTD this year. Can Pfizer shares double to $50 by 2031? What’s Holding Pfizer Back Pfizer is down 0.23% over the past month and essentially flat ... Prediction: Pfizer Stock Will Double on This Date

U.S. FDA expands approval of HYMPAVZI for pediatric hemophilia A and B patients. Label now includes children as young as six, with and without inhibitors. First subcutaneous non factor therapy approved for hemophilia B patients ages 6 to 11. Development is material for Pfizer’s (NYSE:PFE) hemophilia segment and rare disease portfolio. For Pfizer, rare diseases sit alongside vaccines, oncology, and other therapeutics as core parts of its business mix. The broader hemophilia treatment space...